Physician profile
Michelle L Jackson
NPI 1184846529
$11,665.78
in general payments reported to CMS, 2019-2025
35 companies · $2,233 in 2025
The $2,233 reported for 2025 was more than what 79% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $478 · 2021: $1,433 · 2022: $1,591 · 2023: $2,133 · 2024: $2,536 · 2025: $2,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,822 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,822.09 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,228.97 | 2019-2025 | |
| Pfizer INC. | $936.03 | 2019-2025 | |
| Leo Pharma INC. | $891.31 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $827.91 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $758.38 | 2019-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $683.24 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $632.18 | 2019-2025 | Ilumya, Winlevi |
| Lilly USA, LLC | $504.17 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $454.41 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $436.10 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $384.61 | 2019-2025 | |
| Ucb, INC. | $374.95 | 2021-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $365.13 | 2020-2025 | Tremfya |
| Incyte Corporation | $345.80 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $262.25 | 2023-2025 | Zoryve |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $239.65 | 2023-2024 | Vtama |
| Biofrontera INC. | $222.77 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.01 | 2023-2025 | Spevigo |
| Astrazeneca Pharmaceuticals LP | $125.68 | 2021 | |
| Dermira, INC. | $119.82 | 2019-2020 | |
| Strata Skin Sciences, INC. | $118.85 | 2024 | Xtrac |
| Galderma Laboratories, L.P. | $102.42 | 2021-2025 | Aklief, Nemluvio |
| Stemline Therapeutics INC. | $86.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $84.64 | 2021 | |
| Celgene Corporation | $72.96 | 2019 | |
| Almirall LLC | $66.95 | 2021-2024 | Klisyri |
| Mission Pharmacal Company | $33.38 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.59 | 2020-2021 | |
| Prugen, INC. Pharmaceuticals | $27.69 | 2019 | |
| Journey Medical Corporation | $23.11 | 2023 | |
| Organon LLC | $20.43 | 2025 | Vtama |
| Kyowa Kirin, INC. | $19.59 | 2021 | |
| Tempus Ai, INC | $19.02 | 2024 | Merlin Test |
| Cipher Pharmaceuticals US LLC | $15.91 | 2025 | Spinosad, Natroba |
| Tactile Systems Technology INC | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.